Elevance Health is expected to report Q1 2026 revenue of $48.37 billion and earnings per share of $10.61, while the stock currently trades around $323.05, notably below the consensus price target of $384.67.
Investors are primarily focused on the Medical Benefit Ratio (MBR), which is anticipated to rise to 87.5% as the company navigates margin misalignment and elevated cost trends.
Quarterly performance is likely to be impacted by a projected double-digit decline in Medicare Advantage membership and the ongoing effects of Medicaid redeterminations. Management's commentary on the 2027 margin recovery thesis and potential updates to full-year guidance will be critical for sentiment following recent stock underperformance.